Results 31 to 40 of about 5,257 (166)

Pharmacotherapy for Cirrhosis in Japan

Portal Hypertension &Cirrhosis, Volume 4, Issue 2, Page 111-119, June 2025.
As cirrhosis progresses from the compensated to the decompensated stage, liver disease‐related events such as varices, ascites, encephalopathy, sarcopenia, jaundice, and bleeding tendency, as well as liver carcinogenesis, can occur at a high rate. With the advent of new pharmacotherapies for cirrhosis in the last decade, liver fibrosis has been shown ...
Hiroki Nishikawa, Soo Ki Kim, Akira Asai
wiley   +1 more source

Exposure to potentially teratogenic medications before and during the first trimester of pregnancy compared to women of childbearing age: A retrospective analysis of Swiss claims data (2015–2021)

Acta Obstetricia et Gynecologica Scandinavica, Volume 104, Issue 4, Page 707-719, April 2025.
In Switzerland, most dispensed medications with teratogenic effect debated or proven were in the group of weak teratogenicity level. Reassuringly, many women discontinue treatment with potential teratogens before pregnancy. Abstract Introduction Exposure to potentially teratogenic medications during pregnancy is underinvestigated in Switzerland.
Carole A. Marxer, Sereina M. Graber, Daniel Surbek, Alice Panchaud, Christoph R. Meier, Julia Spoendlin   +5 more
wiley   +1 more source

Medication review interventions for adults living with advanced chronic kidney disease: A scoping review

British Journal of Clinical Pharmacology, Volume 91, Issue 4, Page 1132-1156, April 2025.
Abstract Structured medication reviews (SMRs) were introduced into the National Health Service (NHS) Primary Care to support the delivery of the NHS Long‐Term Plan for medicines optimization. SMRs improve the quality of care, reduce harm and offer value for money. However, evidence to support SMRs for patients with chronic kidney disease (CKD) stage G4‐
Cathy Margaret Pogson, Rosalynn Austin, Jignesh Prakash Patel, David Collins Wheeler   +3 more
wiley   +1 more source

A Patient‐Derived 3D Cyst Model of Polycystic Kidney Disease That Mimics Disease Development and Responds to Repurposing Candidates

Clinical and Translational Science, Volume 18, Issue 4, April 2025.
ABSTRACT Autosomal dominant polycystic kidney disease (ADPKD) is the most common hereditary kidney disease. Its progressively expanding, fluid‐filled renal cysts eventually lead to end‐stage renal disease. Despite the relatively high prevalence, treatment options are currently limited to a single drug approved by the FDA and EMA.
Alina Meyer, Bola Khalil, Margarita Iljin, Hester Bange, Leo S. Price, Natalia Dyubankova, Gerard J. P. van Westen, Herman van Vlijmen, Dorien J. M. Peters, Per Artursson   +9 more
wiley   +1 more source

Predictors of the Effect of Tolvaptan on the Prognosis of Cirrhosis

Internal Medicine, 2016
Objective Tolvaptan was first approved for use for cirrhosis in Japan in September 2013. The aim of the study was to examine the effect of tolvaptan, a vasopressin V2 receptor antagonist, on the prognosis of cirrhosis. Methods The effect of tolvaptan was evaluated in 26 patients with cirrhosis treated at our hospital from September 2013 to April 2015 ...
Taro Takami, Tsuyoshi Ishikawa, Takuya Iwamoto, Isao Sakaida, Masaki Maeda, Takuro Hisanaga, Koichi Fujisawa, Toshihiko Matsumoto, Issei Saeki, Isao Hidaka   +9 more
openaire   +4 more sources

Automated Microfluidic Platform for High‐Throughput Biosensor Development

Advanced Sensor Research, Volume 4, Issue 3, March 2025.
Nanopore‐based biosensors are transformative for point‐of‐care diagnostics. This study introduces Bio‐Sensei, a high‐throughput microfluidic IoT platform integrating robotic sampling, electrochemical, and fluorescence setup. Functionalized with an ATCUN peptide for Cu2⁺ detection, it achieves LODs of 10⁻⁶ and 10⁻¹⁵ M in fluorescence and I–V ...
Shitanshu Devrani, Daniel Tietze, Alesia A. Tietze   +2 more
wiley   +1 more source

Prognostic impact of being underweight in patients undergoing mitral TEER: The OCEAN‐Mitral registry

ESC Heart Failure, Volume 12, Issue 1, Page 408-417, February 2025.
Of the patients undergoing mitral transcatheter edge‐to‐edge repair, 20.9% were underweight, with a body mass index less than 18.5 kg/m2. Underweight patients had higher rates of all‐cause, cardiovascular, and non‐cardiovascular mortality, and being underweight was independently associated with all‐cause and cardiovascular mortality.
Ryosuke Higuchi, Masaki Izumo, Yuki Izumi, Mike Saji, Mitsuaki Isobe, Yoshihiro Akashi, Masanori Yamamoto, Masahiko Asami, Yusuke Enta, Masaki Nakashima, Shinichi Shirai, Shingo Mizuno, Yusuke Watanabe, Makoto Amaki, Kazuhisa Kodama, Junichi Yamaguchi, Toru Naganuma, Hiroki Bota, Yohei Ohno, Masahiro Yamawaki, Hiroshi Ueno, Kazuki Mizutani, Shunsuke Kubo, Toshiaki Otsuka, Kentaro Hayashida, on behalf of the OCEAN‐Mitral Investigators   +25 more
wiley   +1 more source

JCS/JHRS 2024 Guideline Focused Update on Management of Cardiac Arrhythmias

Journal of Arrhythmia, Volume 41, Issue 3, June 2025.
Yu‐ki Iwasaki, Takashi Noda, Masaharu Akao, Tadashi Fujino, Teruyuki Hirano, Koichi Inoue, Kengo Kusano, Toshiyuki Nagai, Kazuhiro Satomi, Tetsuji Shinohara, Kyoko Soejima, Yohei Sotomi, Shinya Suzuki, Teiichi Yamane, Tsukasa Kamakura, Hiroyuki Kato, Arimi Katsume, Yusuke Kondo, Kenji Kuroki, Hisaki Makimoto, Hiroshige Murata, Takafumi Oka, Nobuaki Tanaka, Nobuhiko Ueda, Hiro Yamasaki, Seigo Yamashita, Ryobun Yasuoka, Kenji Yodogawa, Kazutaka Aonuma, Takanori Ikeda, Toru Minamino, Hideo Mitamura, Akihiko Nogami, Ken Okumura, Hiroshi Tada, Takashi Kurita, Wataru Shimizu, on behalf of the Japanese Circulation Society and Japanese Heart Rhythm Society Joint Working Group   +37 more
wiley   +1 more source

Tolvaptan and its potential in the treatment of hyponatremia

Therapeutics and Clinical Risk Management, 2008
Tolvaptan is a selective arginine vasopressin (AVP) V(2) receptor blocker used to induce free water diuresis in the treatment of euvolemic or hypervolemic hyponatremia. Currently the orally active medication is in the final stages prior to approval by the FDA for outpatient therapy. It appears to be safe and effective at promoting aquaresis and raising
Y Howard Lien, Megan B Dixon
openaire   +5 more sources

Computational Drug Repositioning in Cardiorenal Disease: Opportunities, Challenges, and Approaches

PROTEOMICS, Volume 25, Issue 11-12, June 2025.
Paul Perco, Matthias Ley, Kinga Kęska‐Izworska, Dorota Wojenska, Enrico Bono, Samuel M. Walter, Lucas Fillinger, Klaus Kratochwill   +7 more
wiley   +1 more source